Dr Lal PathLabs Q1 Net Profit Jumps 29%, Declares Dividend and Approves Two Acquisitions Including Ghana Expansion

The Quick Take

• Dr Lal PathLabs Q1 net profit jumped 29% year-on-year, with revenue rising 19% and EBITDA growing 28.7% to Rs 248 crore from Rs 192 crore
• The company declared an interim dividend and approved two acquisitions, including an 80% stake in Ghana-based Sunshine Healthcare Ltd for up to GHS 45.6 million (~Rs 38 crore)
• The Ghana acquisition marks Dr Lal PathLabs' first entry into West Africa, extending its international diagnostics platform beyond the Middle East and South Asia

Dr Lal PathLabs, India's second-largest diagnostics network, delivered a strong Q1 performance with net profit rising 29% YoY, revenue growing 19%, and EBITDA reaching Rs 248 crore — up 28.7% from Rs 192 crore in the same quarter last year. The results were reported by CNBC TV18 Markets and NDTV Profit, both tier-2 financial news outlets with strong India market credibility. Alongside the earnings, the company's board declared an interim dividend and approved two acquisitions, including the strategically notable purchase of an 80% stake in Ghana-based Sunshine Healthcare Ltd for up to GHS 45.6 million (approximately Rs 38 crore in the first tranche). This marks Dr Lal PathLabs' first presence in West Africa, a geography with significant under-penetration in organised diagnostics and rising health insurance coverage.

The market implications for Dr Lal PathLabs and the Indian diagnostics sector are positive. EBITDA margin expansion alongside strong top-line growth suggests the company is benefiting from both volume recovery post-pandemic normalisation and operational leverage — testing volumes per laboratory are rising while fixed-cost infrastructure is already in place. Peers including Metropolis Healthcare, Thyrocare (part of API Holdings/PharmEasy), and Vijaya Diagnostics will be benchmarked against the 29% profit growth and 28.7% EBITDA growth as their own Q1 results are released. The Ghana acquisition signals that Indian diagnostics chains are now actively pursuing sub-Saharan Africa as a growth geography, where branded healthcare is nascent and first-mover advantages are potentially durable.

The key forward variable is the integration pace and financial contribution of the Ghana acquisition in Q2 and Q3. At Rs 38 crore for 80% in the first tranche, this is a small bet with asymmetric option value if Ghana's health insurance coverage expands as the country's NHI (National Health Insurance Authority) scales. Domestic growth depends on Test volume trajectory in Dr Lal's home markets and whether the second acquisition (details not yet disclosed) is in India or another international geography. Watch for the NDTV Profit Q2 preview to include updated guidance from management on international revenue contribution timelines.

Synthesized from 2 sources.